Biohaven Pharmaceuticals, Inc

215 Church Street New Haven, Connecticut United States of America


  • BHV-0223

Biohaven is a clinical-stage biopharmaceutical company dedicated to the development of innovative drugs targeting neurological diseases, including rare disorders like ALS. We are proud to be able to offer an Expanded Access Program with BHV-0223, a sublingual formulation of riluzole, to eligible patients with ALS for whom other treatment options are insufficient. Clinical trials are the best way to understand a drug's efficacy and safety. Patients entering clinical trials are required to meet specific criteria. For those patients who do not meet these criteria, or if a clinical trial is not available, Expanded Access may be one path for patients to receive our investigational medicines.

Requesting Expanded Access

All requests for Expanded Access must be made by a treating physician on behalf of a patient. Biohaven is committed to a fair and impartial evaluation of each request for access to our investigational medicines. No patient is guaranteed entry into the program by applying. Requests will be acknowledged within two business days.

The BHV0223-401 Expanded Access Program has closed further enrollment.

Additional Resources